BBK Worldwide Expands Mobile Strategy for Patient Recruitment to Include "In-App" Advertising
In an effort to help clinical trial sponsors capitalize on mobile trends and maximize recruitment dollars, BBK Worldwide (BBK) is releasing a suite of advertising tools for mobile applications – designed to increase campaign effectiveness and return on investment. Developed to complement BBK’s existing suite of mobile products and services, this new group of in-app advertising tools creates recruitment opportunities in video, radio, and banner mobile ad networks.
“Mobile advertising has many potential benefits for clinical trial sponsors. Not only does it open doors to untapped audiences of smartphone and tablet users, but it’s very effective when combined with desktop advertising,” comments Lucas Garmon, media strategist, BBK Worldwide. “From a cost-benefit standpoint, the cost per referral is very attractive, making it a savvy consideration for most clinical trial sponsors.”
BBK’s approach to mobile draws upon multiple years of experience and strategic insight into current user trends from its in-house media specialists. To remain competitive in an increasing mobile universe, sponsors must integrate mobile or risk losing out on potential audiences. According to the Pew Internet & American Life Project, 31 percent of cell Internet users surveyed mostly go online using their cell phone, and not using some other device such as a desktop or laptop computer (April 2012).
“Across several campaigns, we’re seeing a tremendous upswing in mobile penetration – including one campaign where we’re seeing that 48 percent of traffic to the study website is resulting from mobile website optimization,” comments Garmon.
BBK is making mobile products and services – and their integration into recruitment initiatives – more attainable for sponsors. The company advocates a strategy-driven multichannel approach. “To remain competitive in today’s marketplace, going mobile is no longer a question but a strategic imperative,” comments Stumm. “Companies lacking a mobile-friendly website drive approximately 61 percent of their mobile traffic to competitors. This is an alarming statistic. If you are weighing the costs to develop a mobile arm to your patient recruitment campaign, it’s important to weigh the risks associated with not having one as well.”
BBK’s suite of mobile recruitment and retention products and services are available for purchase at www.Shop.BBKWorldwide.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
